zibotentan Report issue

Small molecule Experimental
AACT ChEMBL MeSH PubChem

Active Ingredient History

NOW
  • Now
Zibotentan is an experimental anti-cancer drug candidate in development by AstraZeneca. It is an endothelin receptor antagonist.   Wikipedia

Chemistry

  • SMILES: COc1nc(C)cnc1NS(=O)(=O)c1cccnc1-c1ccc(-c2nnco2)cc1
  • InChIKey: FJHHZXWJVIEFGJ-UHFFFAOYSA-N
  • Mol. Mass: 424.44
  • ALogP: 2.71
  • ChEMBL Molecule:
    zibotentan  
More Chemistry

Pharmacology

Alternative names

trans,trans-2(4-methoxyphenyl)-4-(1-3-benzodiazol-5-yl)-1-(dibutylaminocarbonylmethyl)pyrrolidine-3-carboxylic acid | zd4054 | zd-4054 | zibotentan

Organizations (26)

Research & Development (26)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (17)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (17)


 

Breast Neoplasms (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Colorectal Neoplasms (Phase 2)

Healthy Volunteers (Phase 1)

Intermittent Claudication (Phase 2)

Kidney Failure, Chronic (Phase 1)

Liver Cirrhosis (Phase 2)

Liver Diseases (Phase 1)

Lung Neoplasms (Phase 2)

Microvascular Angina (Phase 2)

Neoplasm Metastasis (Phase 2)

Neoplasms (Phase 1)

Ovarian Neoplasms (Phase 2)

Peripheral Arterial Disease (Phase 2)

Prostatic Neoplasms (Phase 3)

Renal Insufficiency, Chronic (Phase 2)

Scleroderma, Systemic (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 29
  • # of Trial Organizations: 26

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue